Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Pulmonx's annualizedGross Profit for the quarter that ended in Dec. 2023 was $57.60 Mil.
Pulmonx's average Total Assets over the quarter that ended in Dec. 2023 was $181.40 Mil. Therefore, Pulmonx's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 31.75%.
Pulmonx Gross-Profit-to-Asset % Historical Data
The historical data trend for Pulmonx's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pulmonx's Gross-Profit-to-Asset %
For the Medical Devices subindustry, Pulmonx's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulmonx's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Pulmonx's Gross-Profit-to-Asset % falls into.
Pulmonx Gross-Profit-to-Asset % Calculation
Pulmonx's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Dec. 2023) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Pulmonx Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Pulmonx's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LUNG has been successfully added to your 